The U.S. Department of Health and Human Services (HHS) has announced proposed updates to the prescribing information for testosterone replacement therapy (TRT) products. The changes could significantly expand treatment access for men with age-related low testosterone and revise several long-standing safety warnings.
The proposal follows a review of new clinical evidence and marks one of the most important changes to testosterone therapy guidelines in more than a decade. If finalized, the updated labels will better reflect current scientific findings and help physicians make informed treatment decisions.
HHS Proposes Major Testosterone Therapy Label Changes
HHS is requesting class-wide labeling revisions for testosterone therapy products. The agency aims to remove previous limitations that questioned the safety and effectiveness of TRT for men with age-related hypogonadism.
In addition, HHS plans to update warnings regarding prostate cancer and benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. The revisions follow a comprehensive review by the FDA and newer clinical data.
Evidence Behind the Decision
The proposed changes rely heavily on findings from the TRAVERSE clinical trial. The study enrolled more than 5,200 men with hypogonadism and cardiovascular risk factors. Researchers compared testosterone therapy with placebo treatment over an average period of 33 months.
The results showed that testosterone therapy did not increase the risk of major cardiovascular events such as heart attacks, strokes, or cardiovascular death. Consequently, regulators concluded that earlier concerns about cardiovascular safety may no longer justify strict labeling restrictions.
Key Changes in Testosterone Therapy Labels
Removal of Age-Related Restrictions
One of the most notable changes is the proposed removal of the “Limitation of Use” statement. Since 2015, labels have stated that testosterone therapy was not proven safe or effective for men with age-related low testosterone.
However, the FDA now believes that current evidence does not support this restriction. As a result, physicians may gain greater flexibility in prescribing TRT to older men experiencing symptoms of testosterone deficiency.
Updated Prostate Cancer Guidance
Current testosterone labels warn that treatment may increase the risk of prostate cancer. Under the proposed revisions, TRT would be contraindicated only for men with metastatic prostate cancer.
Furthermore, FDA reviews have not found consistent evidence linking testosterone therapy to an increased incidence of prostate cancer. Nevertheless, physicians will continue to assess prostate cancer risk before treatment and monitor patients during therapy.
Revised Enlarged Prostate Warnings
HHS also plans to revise warnings related to enlarged prostate conditions. Existing labels caution that TRT may worsen urinary symptoms in men with BPH.
New evidence tells a different story. Clinical studies have shown that men with mild to moderate BPH generally do not experience worsening symptoms while receiving testosterone therapy. However, men with severe symptoms should continue to receive close medical monitoring.
What the Changes Mean for Patients and Physicians
The proposed labeling updates could reshape the treatment landscape for testosterone deficiency. Physicians may feel more comfortable prescribing TRT to eligible patients, especially older men who previously faced barriers due to restrictive labeling.
Patients could also benefit from clearer and more evidence-based information about the therapy’s risks and benefits. Moreover, the changes may help reduce the stigma surrounding testosterone treatment and encourage more discussions about men’s health.
Industry experts believe these revisions represent an important shift toward personalized care. However, healthcare providers will still need to evaluate each patient carefully before starting therapy.
The Science Supporting the New Guidelines
The FDA first introduced stronger warnings for testosterone products in 2015 after concerns emerged regarding cardiovascular risks. Since then, researchers have conducted extensive studies to evaluate the therapy’s long-term safety.
The TRAVERSE trial became one of the largest investigations into testosterone therapy. The study demonstrated that testosterone treatment was not inferior to placebo in terms of cardiovascular safety.
Because of these findings, the FDA removed boxed warnings related to cardiovascular risks in 2025 and added updated blood pressure information. The latest proposal extends those reforms by modernizing additional warnings and usage restrictions.
Conclusion
The HHS proposal to update testosterone therapy labels marks a major shift in men’s healthcare. The changes would remove age-related restrictions, revise prostate cancer warnings, and update guidance for enlarged prostate conditions.
Most importantly, the revisions align product labeling with the latest scientific evidence. If approved, they could expand treatment options and provide physicians and patients with clearer information when considering testosterone replacement therapy.
